XB-002 by Exelixis for Breast Cancer: Likelihood of Approval

XB-002 is under clinical development by Exelixis and currently in Phase II for Breast Cancer.

Dec 22, 2023 - 18:00

XB-002 is under clinical development by Exelixis and currently in Phase II for Breast Cancer.

Read the original article

Tags:

Previous Article

Iruplinalkib by Qilu Pharmaceutical for Solid Tumor: Likelihood of Approval

Imvotamab by IGM Biosciences for Rheumatoid Arthritis: Likelihood of Approval

What's Your Reaction?

0

Like

0

Dislike

0

Love

0

Funny

0

Angry

0

Sad

0

Wow

Related Posts

STAT+: AI leaders issue a plea to Congress: Regulate us, and quickly

STAT+: AI leaders issue a plea to Congress: Regulate us...

May 17, 2023

STAT+: FDA oncology head wants advisory panels to keep voting on new drugs

STAT+: FDA oncology head wants advisory panels to keep ...

Jun 6, 2023

FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for solid tumours

FDA approves Daiichi Sankyo-AstraZeneca’s Enhertu for s...

Apr 9, 2024